Vistagen shares surge 58.55% after fasedienol extension-trial data
AI Summary- Vistagen reported preliminary extension-trial findings for intranasal fasedienol in social anxiety disorder.
- 322 adults received treatment, with 1.6% discontinuing because of adverse events.
- PALISADE-4 missed its overall primary endpoint, while June analysis found benefit in very severe cases.